Integrative molecular analysis of combined small-cell lung carcinoma reveals EGFR and KRAS mutational analysis as the theragnostic tools in whole small cells lung carcinoma landscape

#3345

Introduction: Combined small-cell lung cancer (C-SCLC) are composed of SCLC admixed with a non-small-cell cancer component. They currently receive the same treatment as SCLC. The recent evidence that SCLC may belong to either of 2 lineages, neuroendocrine or non-neuroendocrine, with different vulnerability to specific cell death pathways such as ferroptosis, opens new therapeutic opportunities also for C-SCLC.

Aim(s): These new possibilities related to SCLC heterogeneity are especially implied in C-SCLC, where the tumor lineages could be reflected by the different non-SCLC components.

Materials and methods: 13 C-SCLCs, including 5 with adenocarcinoma (CoADC), 5 with large cell neuroendocrine carcinoma (CoLCNEC) and 3 with squamous cell carcinoma (CoSQC) components, were assessed for alterations in 409 genes and transcriptomic profiling of 20,815 genes.

Conference:

Presenting Author:

Authors: Simbolo M, Centonze G, Ali G, Ciaparrone C, Grillo F,

Keywords: Combined small cell lung carcinoma, small cell lung cancer, neuroendocrine carcinoma, next generation sequencing, transcriptomics,